Apollo Hospitals Enterprise Ltd has announced a significant Rs 573 crore investment from internal accruals to establish a state-of-the-art 100-bed Comprehensive Oncology Centre in Gurugram, marking a major expansion in India's advanced cancer treatment infrastructure. The facility will feature the Proteus One single gantry Proton Beam Therapy system, representing Apollo's third proton therapy installation in India following Chennai and Hyderabad.
Advanced Proton Therapy Technology
The Gurugram center will be integrated as part of the Phase 2 expansion of Apollo's upcoming 500-bed hospital in the city, with completion targeted by FY29. The facility is projected to serve an additional 350 patients annually by FY 2029, significantly expanding access to advanced cancer treatment in the National Capital Region.
"The addition of next-generation proton therapy to our Apollo Proton Cancer Centres further solidifies our position as a global leader in Proton Therapy," said Dr. Prathap C Reddy, Founder-Chairman of Apollo Hospitals.
Strategic Oncology Growth Plans
Apollo has set ambitious targets to double its oncology business to over Rs 5,000 crore in the next 3-4 years. The expansion strategy leverages multiple advanced treatment modalities including high-end personalized care, robotics, immunotherapy, genomics-driven medicine, and CAR-T cell therapies.
This investment underscores Apollo's commitment to expanding its healthcare services and positioning itself at the forefront of precision oncology treatment in India.
Corporate Restructuring for Operational Efficiency
Alongside the oncology investment, Apollo announced plans to acquire the International Finance Corporation's (IFC) 31% stake in Apollo Health and Lifestyle Ltd (AHLL) for Rs 1,254.07 crore. Post-acquisition, AHLL will become a 100% subsidiary of Apollo Hospitals Enterprise Ltd, with 99.42% held by Apollo and the remainder under an ESOP pool.
"This acquisition is a decisive step that will allow for sharper capital allocation and a greater focus on select high-potential segments," said Suneeta Reddy, Managing Director, Apollo Hospitals. "We see AHLL becoming a value-accretive driver in Apollo's integrated healthcare portfolio."
AHLL encompasses primary care and diagnostics, birthing & women's health (Apollo Cradle), ambulatory care centers, dialysis & dental networks. The subsidiary reported a turnover of Rs 1,553.5 crore in FY25, up from Rs 1,365.3 crore in FY24, and is targeting high-teen CAGR growth in diagnostics and primary care, driven by genomics, molecular diagnostics, and personalized health screens.
"By bringing AHLL fully into Apollo's fold, we are sharpening the business focus across its four verticals," said Sangita Reddy, Joint Managing Director. "This sharper focus will enable AHLL to scale more effectively, innovate faster, and serve patients with care models that are more personalized, accessible, and future-ready."
